UNASSIGNED: @entity4616 has been identified as a conduit for @entity2121 resulting in cryptogenic @entity64 or @entity63 ( @entity63 ). We aimed to establish rates of @entity204 , recurrent @entity64 or @entity63 among @entity1 undergoing @entity22105 closure for @entity64 or @entity63 at our unit. A retrospective analysis of all PFO closure @entity1 was performed between May 2004 and January 2013. Follow up was performed by mortality tracing using the Medical Research Information Service of the Office of National Statistics. With regard to @entity64 or @entity63 recurrence, written consent forms and questionnaires were mailed with follow up telephone calls. Medical notes and imaging records were consulted where adverse events were noted. 301 @entity1 aged 48.6        11.0 years, 54.4% male, with >= 1 @entity1031 neurovascular event had percutaneous PFO closure with one of eight devices, with successful implantation in 99% of cases. Follow-up duration was 40.2        26.2 months (range 1.3-105.3); complete in 301 @entity1 for mortality (100%) and 283 @entity1 (94.0%) for @entity531 . Two @entity1 died during follow-up (respiratory failure n   =   1; road traffic accident n   =   1). Recurrent @entity64 (MRI or CT confirmed) was observed in five @entity1 (0.5%; 0.55 per 100 @entity1 -years) and @entity63 in 9 (1.1%; 0.98 per 100 @entity1 -years). @entity955 requiring treatment was documented in 14 @entity1 (1.7%). Percutaneous PFO closure in @entity1 with cryptogenic @entity64 or @entity63 is a safe treatment with a low incidence of procedural complications and recurrent @entity531 . Registry data like these may help to demonstrate the utility of PFO closure in @entity64 .    2015 Wiley Periodicals, Inc.

XXXX closure following cryptogenic @entity64 or transient ischaemic attack: Long-term follow-up of 301 cases.

@entity1 :: ('9606', 'Species') :: ['patients', 'person'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity63 :: ('MESH:D007511', 'Disease') :: ['transient ischemic attack', 'TIA'] @entity2121 :: ('MESH:D019320', 'Disease') :: ['paradoxical embolism'] @entity22105 :: ('CHEBI:60590', 'Chemical') :: ['PFO'] @entity531 :: ('MESH:D013901', 'Disease') :: ['neurovascular events'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolic'] @entity955 :: ('MESH:D001281', 'Disease') :: ['Atrial fibrillation'] @entity4616 :: ('MESH:D054092', 'Disease') :: ['Patent foramen ovale'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death']
@entity4616 :: (MESH:D054092,Disease) :: ['Patent foramen ovale']
